In a case of acute myeloid leukemia we report molecular cytogenetic findings of a t(3;11)(q12;p15), characterized as a new NUP98 translocation rearranging with LOC348801 at chromosome 3. NUP98 involvement was detected by fluorescence in situ hybridization. 3'-RACE-PCR showed nucleotide 1718 (exon 13) of NUP98 was fused in-frame with nucleotide 1248 (exon 2) of LOC348801. RT-PCR and cloning experiments detected two in-frame spliced NUP98-LOC348801 transcripts and the reciprocal LOC348801-NUP98. A highly specific double-color double-fusion FISH assay reliably detects NUP98-LOC348801.
Introduction
Chromosome translocations are recurrent features in hematologic malignancies. In primary and therapy-related acute myeloid leukemia (AML) and in T-cell acute lymphoblastic leukemia (T-ALL), the NUP98 gene, a member of the nucleoporin gene family which maps to chromosome 11p15.5, is a frequent target in chromosomal translocations. To date, 22 diverse NUP98 partners with different characteristics have been described and grouped into homeobox and non-homeobox genes. [1] [2] [3] [4] [5] Here we characterize for the first time fusion of NUP98 and LOC348801 in a case of primary acute myeloid leukemia (AML) with t(3;11)(q12;p15).
Design and Methods

Case report
A 28 year-old man was referred because of fatigue, fever and bleeding. Clinical examination revealed petechia, enlarged liver, spleen and lymph nodes. The peripheral blood count was: Hb 9.1 gr/dL, PLT 30×10 9 /L, WBC 86.4×10 9 /L with 41% blasts. Acute myeloid leukemia M2, according to the FAB classification, was diagnosed on bone marrow. The karyotype was: 46,XY,t(3;11)(q12;p15). The patient achieved hematologic remission after chemotherapy with the HOVON protocol. 6 He relapsed seven months later. Second-line therapy with cytosine arabinoside and mitoxantrone failed. He died 23 months after diagnosis.
Fluorescence in situ hybridization (FISH)
Interphase break-apart FISH assay was performed with clone RP11-348A20 spanning the 5' region and exons 1-27 of NUP98/11p15, and clone CTD-3234F16 spanning the rest of NUP98 and flanking its 3' region. 7 Once the new NUP98 partner was identified at 3q12, we designed a specific doublecolor, double-fusion FISH assay by combining RP11-348A20/CTD-3234F16 for NUP98 (in green) with RP11-683B14, encompassing LOC348801 (in red).
3'-RACE-and RT-PCR
Total RNA was extracted by Trizol (Invitrogen) from the patient's cryopreserved bone marrow cells and 1µg was reverse transcribed using 3'-RACE kit (Invitrogen). cDNA was amplified in semi-nested PCR (Expand extra long PCR system; Roche Applied Science, Penzberg, Germany) using NUP_1083_1106F (exon 8) as the first gene specific primer, NUP_1400_1419F (exon 11) as the second and AUAP (Abridged Universal Amplification Primer, Invitrogen) as reverse primer in both steps. The PCR product was sub-cloned into the pGEM-T easy vector (Promega), sequenced and analyzed using the BLAST program (NCBI, http://www.ncbi.nim.nih.gov/) and BLAT Genome Search (http://genome.ucsc.edu/cgi-bin/hgBlat) programs.
To confirm the NUP98-LOC348801 fusion transcript we performed RT-PCR experiments using primers NUP_1284_1303F (exon 10) and LOC_1843_1824R (exon 4 ) for the first amplification round and primers NUP_1400_1419F (exon 11) and LOC_1787_1768_R (exon 4) for the second.
Primers LOC_1171_1190F (exon 1) and NUP1861_1843R (exon 14) for the first round and primers LOC_1219_1238F (exon 1) and NUP1861_1843R (exon 14) for the second were used to search for the reciprocal fusion transcript.
Results and Discussion
In this first case of primary AML with t(3;11)(q12;p15) characterized by NUP98-LOC348801 fusion, the 5'-region of NUP98 gene encoding GLFG repeats motifs and the GLEBS-like motif was fused in-frame with the 3'-region of LOC348801 gene (Figure 1 ). The reciprocal LOC348801-NUP98 fusion transcript was also present. LOC348801 is the 23 rd gene to be described as a NUP98 fusion partner. It maps to chromosome 3q12.2 and contains four exons encoding for a protein with 178 aminoacids still lacking functional characterization.
The interphase break-apart FISH assay indicated NUP98 was involved in t(3;11)(q12;p15) (data not shown). Our 3'-RACE-PCR experiments showed that nucleotide 1718 (exon 13) of NUP98 was fused in-frame with nucleotide 1248 (exon 2) of LOC348801 (Figure 1) . The genomic breakpoints appeared to fall within intron 13 of NUP98 and intron 1 of LOC348801. Double-color double-fusion FISH which gave one green signal, one red signal, and two fusion signals (Figure 2 ), further confirmed the reciprocal translocation t(3;11)(q12;p15) produced the NUP98-LOC348801 fusion gene.
Interestingly, in LOC348801 nucleotide 1248 is located 33 nucleotides upstream to the ATG start codon (1281-1283) (Figure 1) . Thus, the predicted protein fuses the NUP98 FG repeat motifs and GLEBS-like motif to the entire LOC348801 through an 11 bridging peptide translated from non-coding sequence at the start of LOC348801 exon 2. RT-PCR and cloning experiments detected two in-frame alternatively spliced transcripts. Isoform 1 had NUP98 exon 12, upstream to the breakpoint region while in isoform 2 it was eliminated by alternative splicing (Figure 1 ). Alternative splicing mechanisms were reported in other NUP98 fusions. [8] [9] [10] [11] [12] In mammalians splicing physiologically produces NUP98 or the NUP98-NUP96 mRNA which encodes a precursor protein of 186 kDa. The precursor is then proteolytically cleaved to produce NUP98 and NUP96 proteins. 8, 13 Interestingly, in several oncogenes aberrant and alternative splicing defects may underlie susceptibility to tumor development and progression.
14, 15 Our case emphasizes that alternative splicing is a frequent event in NUP98 leukemic recombinations.
In this patient, a reciprocal LOC348801-NUP98 fusion transcript was also found as nucleotide 1247 (exon 1) of LOC348801 was fused with nucleotide 1719 (exon 14) of NUP98 (data not shown). Reciprocal fusion transcripts were reported in NUP98 translocations with different partners. However, since fusion with a partner may or may not produce the reciprocal transcripts generation does not seem to depend upon the characteristics of the partner gene. [16] [17] [18] Whatever the mechanism, any possible biological and clinical significance of different NUP98 fusion isoforms and/or reciprocal transcripts is still not understood.
To date, t(3;11)(q12;p15) has been reported in two females, one with myelodysplastic syndrome and the other with T-ALL. In both cases NUP98 involvement was proven but partner(s) were not characterized. 1 In another case of primary T-ALL/AML a t(3;11) recombination, which cytogenetically resembled translocation of our patient, was really a 3q translocation/inversion in which NUP98 recombined with the IQCG gene at 3q29. 4 In conclusion NUP98, like MLL, is another promiscuous genes, that rearranges with many partners. In MLLleukemia the translocation partner may influence clinical and phenotype features. 19 Here we describe a new recombination between NUP98 and LOC348801 at 3q12 resulting in two in-frame spliced products and a reciprocal transcript. In our view, molecular characterization of new partners is a step towards a better understanding of the pathogenesis and mechanism of NUP98-positive leukemias. The highly specific double-color double-fusion FISH we set up for the NUP98-LOC348801 fusion provides the differential diagnosis between NUP98-IQCG and NUP98-LOC348801 and rapidly confirms genomic rearrangements, particularly in the event of ambiguous results with conventional cytogenetics.
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